Edition:
United States

Novo Nordisk A/S (NOVOb.CO)

NOVOb.CO on Copenhagen Stock Exchange

277.00DKK
11:10am EDT
Change (% chg)

kr.-0.30 (-0.11%)
Prev Close
kr.277.30
Open
kr.276.40
Day's High
kr.277.20
Day's Low
kr.275.30
Volume
2,696,132
Avg. Vol
3,861,795
52-wk High
kr.384.80
52-wk Low
kr.218.20

Latest Key Developments (Source: Significant Developments)

Novo Nordisk: Novelion CEO leaves board to avoid potential conflict of interest
Tuesday, 16 May 2017 10:18am EDT 

May 16 (Reuters) - Novo Nordisk ::Says Mary Szela steps down from Novo Nordisk's board of directors with immediate effect."The decision follows changed strategic focus for Novelion Therapeutics, a US-based rare disease company, where Ms Szela serves as CEO, which could lead to a potential conflict of interest".  Full Article

Novo Nordisk renews agreement with NNIT
Friday, 5 May 2017 01:24am EDT 

May 5(Reuters) - NNIT A/S ::SAID ON THURSDAY ENTERED INTO A 6-YEAR-AGREEMENT WITH NOVO NORDISK, REPLACING AN EXISTING CORPORATE CORE IT INFRASTRUCTURE OUTSOURCING CONTRACT .SAID RENEWED CONTRACT WILL TAKE EFFECT FROM JAN. 1, 2017 AND RUN UNTIL DEC. 31, 2022.THE NEW AGREEMENT REPRESENTS A TOTAL VALUE OF AROUND 1 BILLION DANISH CROWNS.THE AGREEMENT INCREASES NNIT'S BACKLOG FOR 2018 AND 2019, BUT DOES NOT CHANGE NNIT'S GUIDANCE FOR 2017 OR THE LONG-TERM TARGETS.  Full Article

Novo Nordisk launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in U.S.
Wednesday, 3 May 2017 10:15am EDT 

May 3 (Reuters) - Novo Nordisk A/S : :Launches Xultophy® 100/3.6 (insulin degludec and liraglutide injection) in United States.  Full Article

Novo Nordisk CEO sees lower U.S. political risk
Wednesday, 3 May 2017 02:45am EDT 

May 3 (Reuters) - Danish drugmaker Novo Nordisk's NOVOB.CO chief executive Lars Fruergaard Jorgensen made following comments on a call for journalists, following the firm's first-quarter results::"When we lift the lower end of the range it is mainly because now we are four months into the year and we have not been exposed to any change in the political environment, hence the risk is lower so we feel comfortable about lifting that bottom range"."Where it will end in the United States is hard to predict but simply because we are well into the year we see the risk as having a lower impact on us and that's why we narrow the range".The company narrowed its 2017 forecast to 0 to 3 percent sales growth and -1 to 3 percent operating profit growth from a previous forecast of sales growth of between minus 1 and plus 4 percent, and operating profit of minus 2 percent to plus 3 percent growth, both in local currencies.  Full Article

Drugmaker Novo Nordisk Q1 profit beats forecast, nudges up 2017 outlook
Wednesday, 3 May 2017 01:30am EDT 

May 3 (Reuters) - Novo Nordisk Q1 report::Increased reported operating profit by 10 percent in the first three months of 2017.Q1 sales 28.5 billion DKK versus 27.59 billion DKK seen in Reuters poll.Q1 operating profit 13.5 billion DKK versus 12.00 billion dkk seen in Reuters poll.Q1 net profit 10.2 billion DKK versus 9.03 billion DKK seen in reuters poll.Says for 2017, sales growth is now expected to be in the range of 0 to 3 percent growth, measured in local currencies (previous forecast -1 to +4 percent).Says for 2017, operating profit growth is now expected to be in the range of a decline of 1 to a growth of 3 percent, measured in local currencies (previous forecast -2 to +3 percent).Says for 2017, reported sales growth is now expected to be 1-4 percent measured in Danish kroner, now reflecting a positive currency impact of 1 percentage point .Says reported operating profit growth is now expected to be 0-4 percent measured in Danish kroner, now reflecting a positive currency impact of 1 percentage point.CEO says "with performance in first three months, we are well on track towards our targets for 2017".CEO says "sales were driven by our new, innovative products within diabetes and obesity care, and we are seeing effects of our cost control initiatives, enabling us to invest in future growth opportunities".Says for 2017, now expects financial items (net) to amount to a loss of around DKK 1.8 billion.  Full Article

Novo Nordisk: FDA approves label update for obesity drug Saxenda
Thursday, 27 Apr 2017 11:35am EDT 

April 27 (Reuters) - Danish drug maker Novo Nordisk A/S says::Receives approval of Saxenda (liraglutide) injection 3 mg label update including long-term safety and efficacy data from 3-year trial from U.S. Food and Drug Administration."We are pleased by the FDA's approval, which marks Saxenda as the only weight-loss and management medicine in a pen supported by long-term safety and efficacy data," says Dr. Todd Hobbs, vice president and chief medical officer at Novo Nordisk U.S..For more on the data: ID:nPn2Fr9FBa.  Full Article

Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the U.S
Wednesday, 29 Mar 2017 10:51am EDT 

Novo Nordisk : Says has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the United States Food and Drug Administration (FDA) . Says FDA requested in October additional information related to the assay for the immunogenicity and the assay used to generate the clinical pharmacokinetics data before the review of the NDA could be completed . Says has now evaluated the content of the Complete Response Letter and completed the End-of-Review meeting with FDA .Says expects to receive feedback from FDA in last quarter of 2017.  Full Article

Novo Nordisk launches Fiasp-drug in Canada
Monday, 27 Mar 2017 02:54am EDT 

Novo Nordisk : Says Fiasp, a new, fast-acting mealtime insulin for the treatmentof diabetes in adults, has been launched in Canada on Monday Further company coverage: [NOVOb.CO] (Reporting by Stine Jacobsen) ((stine.jacobsen@thomsonreuters.com;)).  Full Article

EU recommends approval of Novo Nordisk's haemophilia drug
Friday, 24 Mar 2017 08:15am EDT 

EU Medicines Agency: EU Medicines Agency recommendations for March 2017 . Recommends approval of Novo Nordisk's Nonacog Beta Pegol drug for treatment of haemophilia . Recommends approval of Pfizer's Trumenba drug for prophylaxis against invasive meningococcal disease Link to press release: (http://bit.ly/2nv0UIk) Further company coverage: [NOVOB.CO] (Bengaluru Newsroom: +91 806 749 1136).  Full Article

Novo Nordisk gets positive opinion for label update in EU for Tresiba
Friday, 24 Mar 2017 07:30am EDT 

Novo Nordisk : The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials . In the trials, Tresiba, the new-generation once-daily basal insulin, demonstrated clinically relevant reductions in hypoglycaemia compared with insulin glargine U100 in people with type 1 and type 2 diabetes . For the SWITCH 1 trial, the CHMP recommends the updated label to include results reflecting the significant reductions in hypoglycaemia . For the SWITCH 2 trial, the CHMP recommends the updated label to include results reflecting the significant reductions in hypoglycaemia . "An inclusion of the SWITCH trial results in the label will further support the clinical profile of Tresiba," said Mads Krogsgaard Thomsen, chief science officer . The CHMP positive opinion is now referred for final action to the European Commission, which grants approval in the EU .Novo Nordisk expects to receive the updated marketing authorisation in the second quarter of 2017.  Full Article

More From Around the Web

Photo

Novo Nordisk looks to expand Latin American obesity business

COPENHAGEN Danish drugmaker Novo Nordisk is looking to expand its obesity business in Latin America on the back of "phenomenal" performance by its new anti-obesity injection Saxenda, a senior company official said on Monday.